Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink- Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
- Electric Vehicles for Eco-Accommodating Driving
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- Photos: Presidential turkey pardons — a look back
- France's Senate backs ban on social media platforms for under-15s
- Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
